AIManage: Using an AI-driven CDS and Chatbot for the Management of Patients on Incretin Mimetic Medications
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness
研究概览
简要总结
The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH.
The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provider Eligibility Criteria (Phase 1)
- •Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics,
- •Provide care to at least 5 patients prescribed an IMM.
- •Patient Eligibility Criteria (Phase 1)
- •(Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months;
- •Fluency in English or Spanish;
- •Be willing to send/receive text messages; and
- •Be > 18 years of age.
排除标准
- •Provider Exclusion Criteria (Phase 1) • Refuse to participate
- •Patient Exclusion Criteria (Phase 1)
- •Refuse or are unable to provide informed consent;
研究组 & 干预措施
Providers (Phase 1)
Providers prescribing IMM for at least 5 adult patients in primary care and obesity medicine clinics.
干预措施: AIManage (Other)
Patients (Phase 1)
Adult patients prescribed an IMM in the past 6 months.
干预措施: AIManage (Other)
结局指标
主要结局
Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness
时间窗: Day 1 (60 minutes)
In Phase 1, qualitative data regarding perceived usefulness will be collected.
Percentage of Patients who Complete Qualitative Measure - Perceived Usability
时间窗: Day 1 (60 minutes)
In Phase 1, qualitative data regarding perceived usability will be collected.
Percentage of Patients who Complete Qualitative Measure - Perceived Use Challenges
时间窗: Day 1 (60 minutes)
In Phase 1, qualitative data regarding perceived use challenges will be collected.
Percentage of Patients who Complete Qualitative Measure - Perceived Value
时间窗: Day 1 (60 minutes)
In Phase 1, qualitative data regarding perceived value will be collected.
次要结局
未报告次要终点